These terms and conditions govern your use of the website alphaminr.com and its related
services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr,
(“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms
include the provisions in this document as well as those in the Privacy Policy. These terms may
be modified at any time.
Subscription
Your subscription will be on a month to month basis and automatically renew every month. You may
terminate your subscription at any time through your account.
Fees
We will provide you with advance notice of any change in fees.
Usage
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Limitation of Liability
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The
service is provided “As is”. The materials and information accessible through the Service are
solely for informational purposes. While we strive to provide good information and data, we make
no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO
YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY
OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR
(2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE
CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR
CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision
shall not affect the validity or enforceability of the remaining provisions herein.
Privacy Policy
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal
information when we provide our service (“Service”). This Privacy Policy explains how
information is collected about you either directly or indirectly. By using our service, you
acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy
Policy, please do not use our Service. You should contact us if you have questions about it. We
may modify this Privacy Policy periodically.
Personal Information
When you register for our Service, we collect information from you such as your name, email
address and credit card information.
Usage
Like many other websites we use “cookies”, which are small text files that are stored on your
computer or other device that record your preferences and actions, including how you use the
website. You can set your browser or device to refuse all cookies or to alert you when a cookie
is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not
function properly. We collect information when you use our Service. This includes which pages
you visit.
Sharing of Personal Information
We use Google Analytics and we use Stripe for payment processing. We will not share the
information we collect with third parties for promotional purposes.
We may share personal information with law enforcement as required or permitted by law.
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
September 30,
2025
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
Commission File Number
001-32157
Savara Inc.
(Exact name of registrant as specified in its charter)
Delaware
84-1318182
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
1717 Langhorne Newtown Road
,
Suite 300
Langhorne
,
Pennsylvania
19047
(Address of principal executive offices)
(Zip Code)
(
512
)
614-1848
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
SVRA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ☐
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
☒
As of November 12, 2025, the registrant had
203,467,845
shares of common stock, $0.001 par value per share, outstanding.
(In thousands, except share and per share amounts)
September 30, 2025
December 31, 2024
(Unaudited)
Assets
Current assets:
Cash and cash equivalents
$
16,277
$
15,128
Short-term investments
108,109
181,199
Prepaid expenses and other current assets
3,812
5,808
Total current assets
128,198
202,135
Property and equipment, net
85
165
In-process R&D
11,651
10,337
Other non-current assets
990
242
Total assets
$
140,924
$
212,879
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
4,136
$
4,545
Accrued expenses and other current liabilities
12,621
10,179
Total current liabilities
16,757
14,724
Long-term liabilities:
Long-term debt
29,781
26,619
Other long-term liabilities
—
87
Total liabilities
46,538
41,430
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, $
0.001
par value,
300,000,000
authorized as of September 30, 2025 and
December 31, 2024;
172,850,443
and
172,423,223
shares issued and outstanding
as of September 30, 2025 and December 31, 2024, respectively
173
173
Additional paid-in capital
670,219
661,276
Accumulated other comprehensive loss
(
155
)
(
750
)
Accumulated deficit
(
575,851
)
(
489,250
)
Total stockholders' equity
94,386
171,449
Total liabilities and stockholders’ equity
$
140,924
$
212,879
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
Savara Inc. and Subsidiaries
Condensed Consolidated Statements of
Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
For the three months ended September 30,
For the nine months ended September 30,
2025
2024
2025
2024
Operating expenses:
Research and development
$
20,592
$
20,311
$
60,502
$
54,735
General and administrative
9,627
6,013
29,528
17,189
Depreciation and amortization
36
33
98
98
Total operating expenses
30,255
26,357
90,128
72,022
Loss from operations
(
30,255
)
(
26,357
)
(
90,128
)
(
72,022
)
Other income (expense)
Interest income
548
2,129
2,967
4,554
Foreign currency exchange gain (loss)
146
(
20
)
322
(
166
)
Tax credit income
—
—
784
797
Loss on extinguishment of debt
—
—
(
546
)
—
Total other income, net
694
2,109
3,527
5,185
Net loss
$
(
29,561
)
$
(
24,248
)
$
(
86,601
)
$
(
66,837
)
Net loss per share:
Basic and diluted
$
(
0.14
)
$
(
0.11
)
$
(
0.40
)
$
(
0.35
)
Weighted-average common shares outstanding:
Basic and diluted
216,462,161
211,847,651
216,347,963
192,398,514
Other comprehensive income (loss):
Gain (loss) on foreign currency translation
(
62
)
596
712
263
Unrealized gain (loss) on short-term
investments
123
583
(
117
)
307
Total comprehensive loss
$
(
29,500
)
$
(
23,069
)
$
(
86,006
)
$
(
66,267
)
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
Savara Inc. and Subsidiaries
Condensed Consolidated Statements of Changes
in Stockholders’ Equity
Periods Ended September 30, 2025 and 2024
(In thousands, except share amounts)
(Unaudited)
Stockholders’ Equity
Common Stock
Number of
Shares
Amount
Additional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income (Loss)
Total
Balance on December 31, 2024
172,423,223
$
173
$
661,276
$
(
489,250
)
$
(
750
)
$
171,449
Issuance of common stock upon
exercise of stock options
100,250
—
165
—
—
165
Issuance of common stock for
settlement of RSUs
255,000
—
—
—
—
—
Repurchase of shares for
minimum tax withholdings
(
75,083
)
—
(
215
)
—
—
(
215
)
Stock-based compensation
—
—
2,972
—
—
2,972
Foreign exchange translation
adjustment
—
—
—
—
272
272
Unrealized loss on short-term
investments
—
—
—
—
(
154
)
(
154
)
Net loss
—
—
—
(
26,639
)
—
(
26,639
)
Balance on March 31, 2025
172,703,390
$
173
$
664,198
$
(
515,889
)
$
(
632
)
$
147,850
Issuance of common stock upon
exercise of stock options
44,250
—
65
—
—
65
Issuance of common stock for
settlement of RSUs
125,000
—
—
—
—
—
Repurchase of shares for
minimum tax withholdings
(
35,718
)
—
(
115
)
—
—
(
115
)
Stock-based compensation
—
—
2,669
—
—
2,669
Foreign exchange translation
adjustment
—
—
—
—
502
502
Unrealized loss on short-term
investments
—
—
—
—
(
86
)
(
86
)
Net loss
—
—
—
(
30,401
)
—
(
30,401
)
Balance on June 30, 2025
172,836,922
$
173
$
666,817
$
(
546,290
)
$
(
216
)
$
120,484
Issuance of common stock for
settlement of RSUs
20,000
—
—
—
—
—
Repurchase of shares for
minimum tax withholdings
(
6,479
)
—
(
23
)
—
—
(
23
)
Stock-based compensation
—
—
3,425
—
—
3,425
Foreign exchange translation
adjustment
—
—
—
—
(
62
)
(
62
)
Unrealized gain on short-term
investments
—
—
—
—
123
123
Net loss
—
—
—
(
29,561
)
—
(
29,561
)
Balance on September 30, 2025
172,850,443
$
173
$
670,219
$
(
575,851
)
$
(
155
)
$
94,386
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Savara Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders’ Equity (continued)
Periods Ended September 30, 2025 and 2024
(In thousands, except share amounts)
(Unaudited)
Stockholders’ Equity
Common Stock
Number of
Shares
Amount
Additional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income (Loss)
Total
Balance on December 31, 2023
138,143,545
$
140
$
533,872
$
(
393,369
)
$
(
271
)
$
140,372
Issuance of common stock upon
exercise of options
31,914
—
51
—
—
51
Issuance of common stock for
settlement of RSUs
1,563
—
—
—
—
—
Repurchase of shares for
minimum tax withholdings
(
381
)
—
(
2
)
—
—
(
2
)
Stock-based compensation
—
—
2,257
—
—
2,257
Foreign exchange translation
adjustment
—
—
—
—
(
220
)
(
220
)
Unrealized gain on short-term
investments
—
—
—
—
(
251
)
(
251
)
Net loss
—
—
—
(
20,346
)
—
(
20,346
)
Balance on March 31, 2024
138,176,641
$
140
$
536,178
$
(
413,715
)
$
(
742
)
$
121,861
Issuance of common stock upon
exercise of options
21,225
—
11
—
—
11
Issuance of common stock for
settlement of RSUs
1,562
—
—
—
—
—
Repurchase of shares for
minimum tax withholdings
(
381
)
—
(
2
)
—
—
(
2
)
Reimbursement of commissions from
the prior issuance of common stock
upon at the market sales, net
—
—
46
—
—
46
Stock-based compensation
—
—
2,196
—
—
2,196
Foreign exchange translation
adjustment
—
—
—
—
(
113
)
(
113
)
Unrealized loss on short-term
investments
—
—
—
—
(
25
)
(
25
)
Net loss
—
—
—
(
22,243
)
—
(
22,243
)
Balance on June 30, 2024
138,199,047
$
140
$
538,429
$
(
435,958
)
$
(
880
)
$
101,731
Issuance of common stock in
underwritten public offering,
net of offering costs
26,246,720
26
93,773
—
—
93,799
Issuance of common stock upon at
the market offerings, net
6,038,650
6
24,368
—
—
24,374
Issuance of common stock upon
exercise of stock options
303,796
—
237
—
—
237
Issuance of common stock for
settlement of RSUs
76,563
—
—
—
—
—
Repurchase of shares for
minimum tax withholdings
(
22,013
)
—
(
94
)
—
—
(
94
)
Stock-based compensation
—
—
2,371
—
—
2,371
Foreign exchange translation
adjustment
—
—
—
—
596
596
Unrealized gain on short-term
investments
—
—
—
—
583
583
Net loss
—
—
—
(
24,248
)
—
(
24,248
)
Balance on September 30, 2024
170,842,763
$
172
$
659,084
$
(
460,206
)
$
299
$
199,349
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Savara Inc. and Subsidiaries
Condensed Consolidated S
tatements of Cash Flows
(In thousands)
(Unaudited)
For the nine months ended September 30,
2025
2024
Cash flows from operating activities:
Net loss
$
(
86,601
)
$
(
66,837
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
98
98
Reduction in the carrying value of right-of-use assets
118
107
Amortization of debt issuance costs
327
203
Loss on extinguishment of debt
546
—
Accretion on discount to short-term investments
(
2,376
)
(
3,972
)
Stock-based compensation
9,066
6,824
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
2,451
(
3,357
)
Non-current assets
(
768
)
(
814
)
Accounts payable and accrued expenses and other current liabilities
1,159
1,941
Net cash used in operating activities
(
75,980
)
(
65,807
)
Cash flows from investing activities:
Purchase of property and equipment
(
20
)
(
34
)
Purchase of available-for-sale securities, net
(
77,656
)
(
172,852
)
Maturity of available-for-sale securities
152,800
115,050
Net cash provided by (used in) investing activities
75,124
(
57,836
)
Cash flows from financing activities:
Repayment of long-term debt
(
27,229
)
—
Proceeds from long-term debt, net
29,598
—
Issuance of common stock in underwritten public offering, net of offering costs
—
93,799
Issuance of common stock upon at the market offerings, net
—
24,374
Proceeds from exercise of stock options
230
299
Reimbursement of commissions from the prior issuance of common
stock upon at the market sales, net
—
46
Repurchase of shares for minimum tax withholdings
(
353
)
(
98
)
Net cash provided by financing activities
2,246
118,420
Effect of exchange rate changes on cash and cash equivalents
(
241
)
65
Increase (decrease) in cash and cash equivalents
1,149
(
5,158
)
Cash and cash equivalents beginning of period
15,128
26,585
Cash and cash equivalents end of period
$
16,277
$
21,427
Supplemental disclosure of cash flow information:
Cash paid for interest
$
2,544
$
1,619
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Savara Inc. and Subsidiaries
Notes to Condensed Consolidated F
inancial Statements (Unaudited)
1. Organization and Nature of Operations
Description of Business
Savara Inc. (together with its subsidiaries “Savara,” the “Company,” “we” or “us”) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company’s sole program, molgramostim inhalation solution ("MOLBREEVI"), is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis (“autoimmune PAP”). The Company and its wholly-owned domestic and foreign subsidiaries operate in one segment with its principal office in Langhorne, Pennsylvania, though a significant portion of employees work remotely.
Since inception, Savara has devoted its efforts and resources to identifying and developing its product candidates, recruiting personnel, and raising capital. Savara has incurred operating losses and negative cash flow from operations and has
no
product revenue from inception to date. The Company has not yet commenced commercial operations.
2. Summary of Significant Accounting Policies
Basis of Presentation
The unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) as defined by the Financial Accounting Standards Board (“FASB”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments that are necessary to fairly present the statements of financial position, operations and cash flows for the periods presented. The results of operations for interim periods shown in this report are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any other future annual or interim period.
Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted from these condensed consolidated financial statements, as permitted by rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The Company believes the disclosures made in these condensed consolidated financial statements are adequate to make the information herein not misleading. The Company recommends that these condensed consolidated financial statements be read in conjunction with its audited consolidated financial statements and related notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2024. The Company’s significant accounting policies are described in Note 2 to the audited consolidated financial statements. There have been no changes to the Company's significant accounting policies since the date of those financial statements.
Principles of Consolidation
The interim condensed consolidated financial statements of the Company are stated in U.S. dollars and are prepared under U.S. GAAP. These condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The financial statements of the Company’s wholly-owned subsidiaries are recorded in their functional currency and translated into the reporting currency. The cumulative effect of changes in exchange rates between the foreign entity’s functional currency and the reporting currency is reported in
Accumulated other comprehensive loss
in the condensed consolidated balance sheet. All intercompany transactions and accounts have been eliminated in consolidation. The condensed consolidated balance sheet at December 31, 2024 has been derived from the Company's audited consolidated financial statements at that date but does not include all of the information and notes required by U.S. GAAP for complete financial statements.
Liquidity
As of September 30, 2025, the Company had an accumulated deficit of approximately
$
575.9
million
, cash and cash equivalents of
$
16.3
million
and short-term investments of
$
108.1
million
. The Company used cash in operating activities of approximately
$
76.0
million
during the nine months ended September 30, 2025. On October 31, 2025 the Company completed a public offering of its common stock and certain pre-funded warrants which resulted in net proceeds to the Company of approximately $140.0 million, after deducting final underwriting discounts, commissions, and other estimated offering expenses and including the underwriter's option to purchase additional shares of our common stock at the public offering price. The Company's cash and cash equivalents and short-term investments are sufficient to fund the Company’s operations for at least the next twelve months subsequent to the issuance date of these condensed consolidated financial statements. The Company is currently focused on the development of MOLBREEVI for the treatment of autoimmune PAP and believes such activities will result in the continued incurrence of significant research and development, regulatory and
6
other expenses related to this program. If the Company’s product candidate does not gain regulatory approval or, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash and cash equivalents on hand, short-term investments, and through a combination of equity offerings, debt financings, government or other third-party funding, and other collaborations and strategic alliances with partner companies. The Company cannot be sure that additional financings will be available when needed or that, if available, financings will be obtained on terms favorable to the Company or its stockholders. If such additional financings are not available timely and at adequate levels, the Company will need to reevaluate its long-term operating plans. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
In order to mitigate risks associated with our banking deposits, the Company maintains a significant portion of its liquidity in U.S. Treasury money market funds and other short-term investments with custodial services provided by U.S. Bank, N.A., and FNZ, refer to
Note 5. Short-term Investments
and
Note 7. Fair Value Measurements
.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management’s estimates include those related to the accrual of research and development and general and administrative costs, certain financial instruments recorded at fair value, stock-based compensation, and the valuation allowance for deferred tax assets.
The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates.
Risks and Uncertainties
The product candidate being developed by the Company requires approval from the U.S. Food and Drug Administration (“FDA”) or foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company’s product candidate will receive the necessary approvals. If the Company is denied regulatory approval of its product candidate, or if approval is delayed, it will have a material adverse impact on the Company’s business, results of operations, and its financial position.
The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery and development of drug candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology, and market acceptance of the Company’s product. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company’s future success.
Concentration of Credit Risk
We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalents and marketable securities with a limited number of financial institutions. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets.
Recent Accounting Pronouncements
In December 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard is effective for public companies for all annual periods beginning after December 15, 2024, with early adoption permitted. ASU 2023-09 will be effective for the Company beginning with its 2025 annual financial statements. The Company is in the process of evaluating the impact that the adoption of this ASU may have on its condensed consolidated financial statements and related disclosures.
In November 2024, the FASB issued ASU No 2024-03—Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). The guidance in ASU 2024-03 is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the
7
face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is in the process of evaluating the impact that the adoption of this ASU may have on its condensed consolidated financial statements and related disclosures.
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which includes significant changes to federal tax law and other regulatory provisions that may impact the Company. The OBBBA contains several changes to corporate taxation including modifications to capitalization of research and development expenses, limitations on deductions for interest expense and accelerated fixed asset depreciation. The Company is currently evaluating the provisions of the new law and the potential effects on its financial position, results of operations, and cash flows. As of the date of these condensed consolidated financial statements, the Company has not completed its assessment, and therefore no adjustments have been made. Additional disclosures will be provided in future periods as the impact of the legislation is determined.
There are no other recent accounting pronouncements issued by the FASB, the American Institute of Certified Public Accountants, or the SEC that are believed by the Company's management to have a material effect, if any, on the Company’s condensed consolidated financial statements.
3. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):
September 30, 2025
December 31, 2024
Prepaid contracted research and development costs
$
2,012
$
4,179
R&D tax credit receivable
866
768
Prepaid insurance
168
131
VAT receivable
234
275
Deposits and other
532
455
Total prepaid expenses and other current assets
$
3,812
$
5,808
Prepaid Contracted Research and Development Costs
As of September 30, 2025,
Prepaid
contracted research and development costs
are primarily comprised of contractual prepayments associated with the Company's clinical trial for MOLBREEVI for the treatment of autoimmune PAP. This includes prepaid amounts paid under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers that provide services in connection with the Company's research and development activities.
R&D Tax Credit Receivable
The Company has recorded a Danish tax credit earned by its subsidiary, Savara ApS, as of September 30, 2025
. Under Danish tax law, Denmark remits a research and development tax credit equal to
22
% of qualified research and development expenditures, not to exceed established thresholds. During the year ended
December 31, 2024, the Company generated a Danish tax credit of
$
0.9
million, which is included in
Prepaid expenses and other current assets
and is expected to be received in the fourth quarter of 2025. During the nine months ended September 30, 2025, the Company generated a Danish tax credit of
$
0.9
million, which is recorded in
Other non-current assets
in the condensed consolidated balance sheet and is expected to be received in the fourth quarter of 2026
.
4. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of (in thousands):
September 30, 2025
December 31, 2024
Accrued contracted research and development costs
$
7,452
$
3,912
Accrued compensation
3,915
$
5,017
Accrued general and administrative costs
1,205
1,134
Lease liability
49
116
Total accrued expenses and other current liabilities
$
12,621
$
10,179
8
Accrued Contracted Research and Development Costs
As of September 30, 2025,
Accrued contracted research and development costs
are primarily comprised of costs associated with MOLBREEVI for the treatment of autoimmune PAP, including expenses resulting from obligations under agreements with CROs, CMOs, and other outside service providers that provide services in connection with the Company's research and development activities.
Accrued Compensation
As of September 30, 2025,
Accrued compensation
includes amounts to be paid to employees for salary, bonuses, vacation and non-equity performance-based compensation. At the end of any period, the amounts accrued for such compensation may vary due to many factors including, but not limited to, timing of payments to employees and vacation usage.
5. Short-term Investments
The Company’s investment policy seeks to preserve capital and maintain sufficient liquidity to meet operational and other needs of the business. The following table summarizes, by major security type, the Company’s investments (in thousands):
As of September 30, 2025
Amortized Cost
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value
Short-term investments
U.S. government securities
$
107,992
$
117
$
—
$
108,109
Total short-term investments
$
107,992
$
117
$
—
$
108,109
As of December 31, 2024
Amortized Cost
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value
Short-term investments
U.S. government securities
$
180,961
$
255
$
(
17
)
$
181,199
Total short-term investments
$
180,961
$
255
$
(
17
)
$
181,199
The Company has classified its investments as available-for-sale securities. These securities are carried at estimated fair value with the aggregate unrealized gains and losses related to these investments reflected as a part of
Accumulated other comprehensive loss
in the condensed consolidated balance sheet. Classification as short-term or long-term is based upon whether the initial maturity of the debt securities is less than or greater than twelve months, as further discussed in
Note 7 . Fair Value Measurements
.
There were
no
significant realized gains or losses related to investments for the
nine months ended September 30, 2025 and 2024
.
6.
Debt
Facility
On March 26, 2025 (the “Closing Date”), the Company, as borrower, entered into a Loan and Security Agreement (the “Hercules Loan Agreement”) with the lenders party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent. The Hercules Loan Agreement provides for the Company to borrow up to $
200
million of term loans (the “Term Loan”) that may be advanced in multiple tranches.
The initial advance of $
30
million under the Hercules Loan Agreement was drawn on the Closing Date and used to repay all outstanding obligations under the Company’s prior term loan with Silicon Valley Bank ("SVB Loan"), to pay the Company’s expenses in connection with the Hercules Loan Agreement, and for general corporate purposes. The Company may make further draws in the following tranches: (i) subject to FDA approval of the Company’s MOLBREEVI product candidate for the treatment of
autoimmune PAP
(the “Approval Milestone”), (a) up to $
40
million on or prior to March 15, 2026 and (b) up to $
40
million on or prior to December 15, 2026; (ii) subject to the Company achieving a trailing six months' net product revenue from the sale of MOLBREEVI of at least
seventy-five
percent of an agreed upon revenue plan for any reporting period following March 31, 2027 (the “Revenue Milestone”), up to $
20
million on or prior to December 31, 2027; and (iii) subject to approval by the Lenders’ investment committees, up to $
70
million.
The Term Loan will mature
April 1, 2030
(the “Maturity Date”). Amounts outstanding under the Term Loan bear interest at a floating rate equal to (i) the greater of (a) the prime rate reported in The Wall Street Journal or (b)
6.0
%, plus (ii)
1.45
%, or, subject to the Company meeting the Revenue Milestone, a
25
bps reduction in the interest rate after the full fiscal quarter following such achievement. The Term Loan has an interest-only monthly payment through March 2028 (the “Interest-Only Period”), and beginning April 1, 2028, requires equal monthly installments of principal plus interest until the Maturity Date. If the Company achieves the Approval Milestone, the Interest-Only period will extend until the Maturity Date.
9
The Company's obligations under the Hercules Loan Agreement are secured, subject to customary permitted liens and other agreed-upon exceptions, by a first-priority perfected security interest in all of the tangible and intangible assets of the Company, other than intellectual property, on which there is a negative pledge. The Hercules Loan Agreement includes customary affirmative and negative covenants, repayment terms, prepayment terms subject to a
1.0
% or
2.0
% penalty of the amount prepaid as determined when payment occurs following the Closing Date, a contingent prepayment requirement, with any prepayment penalties waived, upon the acquisition or change of control of the Company as defined within the Hercules Loan Agreement, representations and warranties, and events of default, consisting of some events not related to the creditworthiness of the Company, which if triggered, permit the Lenders to accelerate repayment of any outstanding loan amount at the Lenders' discretion. In the event any payment is not paid on the scheduled payment date or upon an aforementioned non-creditworthiness event of default, which may trigger a call feature by the Lenders, an amount equal to
4.0
% of such past due amount shall be payable on demand (collectively, the "Default Penalty").
The Hercules Loan Agreement contains an affirmative covenant requiring the Company to maintain unrestricted cash under an account control agreement equal to
50
% of the outstanding principal of the Term Loan beginning April 1, 2026 (the “Cash Requirement”), which will decrease to
35
% upon achievement of the Revenue Milestone and compliance with the Conditional Minimum Revenue Covenant (defined below). However, if the Approval Milestone has not been achieved, the Cash Requirement increases to
70
% of the outstanding principal until the Approval Milestone is achieved. Notwithstanding the foregoing, the Cash Requirement will not apply during any period when the Company’s market capitalization exceeds $
600
million.
Additionally, if the Company draws more than $
50
million under the Term Loan, beginning nine months after achievement of the Approval Milestone, the Company will be required to have achieved, and to maintain, trailing six months of net product revenue of at least (i)
65
% of a provided sales forecast or (ii) $
100
million (“Conditional Minimum Revenue Covenant”). If the Company raises at least $
75
million in net cash proceeds from the issuance of equity and/or upfront business development proceeds before June 30, 2026, the Conditional Minimum Revenue Covenant will not apply until 15 months after achievement of the Approval Milestone. Notwithstanding the foregoing, the Conditional Minimum Revenue Covenant will not apply during any period when the Company’s market capitalization exceeds $
500
million and the Company maintains minimum unrestricted cash under an account control agreement equal to
50
% of the outstanding principal amount of the Term Loan.
The Company is obligated to pay customary closing fees, a facility charge equal to
0.5
% of the initial tranche at the Closing Date and upon any additional tranches drawn by the Company during the term of the Hercules Loan Agreement, and an end of term charge based upon the outstanding principal balance equal to
3.95
% if repayment occurs within 24 months of the Closing Date,
4.95
% if repayment occurs after 24 months and before 36 months of the Closing Date,
5.95
% if repayment occurs after 36 months and before 48 months of the Closing Date, and
6.95
% if repayment occurs after 48 months from the Closing Date.
As of September 30, 2025
, approximately $
0.5
million of fees consisting of legal, commitment and facility charges, paid to the Lenders were capitalized and will be amortized over the term of the Hercules Loan Agreement.
The Company has identified certain embedded features within the Hercules Loan Agreement. The Company assessed these features and determined the one feature related to Default Penalty interest due upon an event of default is required to be bifurcated from the debt and accounted for separately at fair value. As of September 30, 2025, the Default Penalty does not have a discernable fair value and no amounts are recorded.
The Company accounted for the repayment of the SVB Loan as an extinguishment in accordance with the guidance in ASC 470-50 and recognized a loss associated with the extinguishment of approximately
$
0.5
million in other income (expense) in the accompanying condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2025.
10
Summary of Carrying Value
The following table summarizes the components of the long-term debt carrying value, which approximates the fair value (in thousands):
Future minimum payments due during the year ended December 31,
September 30, 2025
2025
$
—
2026
—
2027
—
2028
11,297
2029
14,747
2030
6,041
Total future minimum payments
32,085
Unamortized end of term charge
(
1,871
)
Debt fees
(
433
)
Debt discount related to warrants
—
Total debt
29,781
Current portion of long-term debt
—
Long-term debt
$
29,781
7. Fair Value Measurements
The Company measures and reports certain financial instruments at fair value on a recurring basis and evaluates its financial instruments subject to fair value measurements on a recurring and nonrecurring basis to determine the appropriate level in which to classify them in each reporting period.
Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
Certain assets and liabilities are measured at fair value on a nonrecurring basis. These assets and liabilities are not measured at fair value on an ongoing basis, but are subject to fair value adjustments annually or whenever events or circumstances indicate that the carrying value of those assets may not be recoverable. These assets and liabilities can include acquired in-process research and development (“IPR&D”) and other long-lived assets that are written down to fair value if they are impaired.
During the nine months ended September 30, 2025 and 2024, the Company experienced an increase of approximately
$
1.3
million
and an increase of approximately
$
0.2
million, respectively, in the carrying value of IPR&D due to foreign currency translation.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company determined that certain investments in debt securities classified as available-for-sale securities were Level 1 financial instruments.
Additional investments in corporate debt securities, commercial paper, and asset-backed securities are considered Level 2 financial instruments because the Company has access to quoted prices but does not have visibility to the volume and frequency of trading for all of these investments. For the Company’s investments, a market approach is used for recurring fair value measurements and the valuation techniques use inputs that are observable, or can be corroborated by observable data, in an active marketplace.
11
The fair value of these instruments as of
September 30, 2025 and December 31, 2024 was as follows (in thousands):
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
As of September 30, 2025
Cash equivalents:
U.S. Treasury money market funds
$
15,580
$
—
$
—
$
15,580
Short-term investments:
U.S. government securities
108,109
—
—
108,109
As of December 31, 2024
Cash equivalents:
U.S. Treasury money market funds
$
13,802
$
—
$
—
$
13,802
Short-term investments:
U.S. government securities
181,199
—
—
181,199
The Company did
no
t transfer any assets measured at fair value on a recurring basis to or from Level 1, Level 2, and Level 3 during the
nine months ended September 30, 2025 and 2024
.
8. Stockholders’ Equity
Evercore Common Stock Sales Agreement Termination
On
July 6, 2021
, the Company entered into a Sales Agreement with Evercore Group L.L.C. (“Evercore”), as sales agent (the “ATM Agreement”), permitting the Company to offer and sell up to an aggregate of $
100.0
million of shares of its common stock, par value $
0.001
per share, from time to time through Evercore in “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended.
On March 31, 2025, pursuant to Section 12(b) of the ATM Agreement, the Company delivered written notice to Evercore that it was terminating the ATM Agreement, effective
April 2, 2025
. The Company is not subject to any termination penalties related to the termination of the ATM Agreement.
During the nine months ended September 30, 2024, the Company sold 6,038,650 shares of the Company’s common stock to a single institutional investor pursuant to the Sales Agreement resulting in net proceeds of $24.4 million. The Company did not sell any shares of common stock under the Sales Agreement during the nine months ended September 30, 2025.
July 2024 Underwritten Offering of Common Stock
On July 1, 2024, the Company sold an aggregate of
26,246,720
shares of the Company’s common stock, par value $
0.001
per share, pursuant to an underwritten offering of its common stock (the "July 2024 Offering") at an offering price of $
3.81
per share. The July 2024 Offering was made pursuant to the Registration Statement on Form S-3 (File No. 333-279274), which was filed with the SEC on May 9, 2024 and declared effective on May 21, 2024 (the "2024 Registration Statement"), and a prospectus supplement filed with the SEC on June 28, 2024. The July 2024 Offering resulted in net proceeds of $
93.8
million after taking into consideration underwriter commissions, legal fees, and other customary closing costs.
Common Stock Reserved for Issuance
The Company’s shares of common stock reserved for issuance as of the periods indicated were as follows:
September 30, 2025
December 31, 2024
April 2017 Warrants
24,725
24,725
June 2017 Warrants
41,736
41,736
December 2018 Warrants
11,332
11,332
Pre-funded PIPE Warrants
5,780,537
5,780,537
2021 Pre-funded Warrants
32,175,172
32,175,172
2023 Pre-funded Warrants
5,666,667
5,666,667
Stock options outstanding
13,209,871
13,554,621
Issued and nonvested RSUs
4,093,000
4,677,500
Total shares reserved
61,003,040
61,932,290
12
Warrants
The following table summarizes the outstanding warrants for the Company’s common stock as of
September 30, 2025:
Expiration Date
Shares Underlying
Outstanding Warrants
Exercise Price
April 2027
24,725
$
2.87
June 2027
41,736
$
2.87
December 2028
11,332
$
2.87
None
43,622,376
$
0.001
43,700,169
Accumulated Other Comprehensive Loss Information
The components of accumulated other comprehensive loss as o
f the dates indicated and the change during the period were (in thousands):
Foreign Exchange Translation Adjustment
Unrealized Gain (Loss) on ST Investments
Total Accumulated Other Comprehensive Loss
Balance, December 31, 2023
$
(
461
)
$
190
$
(
271
)
Change
$
(
523
)
$
44
$
(
479
)
Balance, December 31, 2024
$
(
984
)
$
234
$
(
750
)
Change
$
712
$
(
117
)
$
595
Balance, September 30, 2025
$
(
272
)
$
117
$
(
155
)
9. Commitments
and Contingencies
Manufacturing and Other Commitments and Contingencies
The Company has entered into a number of contracts for the manufacture of its product candidate, MOLBREEVI. Some of these, as enumerated below entail various royalties and manufacturing and development payments.
FujiFilm Diosynth (“Fuji”)
In February 2024, the Company entered into a master services agreement with Fuji to provide development and manufacturing services related to the active pharmaceutical ingredient (“API”) for the Company’s MOLBREEVI product candidate in accordance with the terms of separate scope of work agreements and to perform a manufacturing campaign for process performance qualification of the API of MOLBREEVI. The total estimated accumulated fees the Company will have paid this manufacturer for services under that master services agreement and related work orders and subsequent change orders is $31.6 million. Amounts payable for future services are subject to various cancellation fees ranging from ten percent (10%) to one hundred percent (100%) of the cost of the respective activity based upon the timing of the commencement date and status of the activity.
GEMABIOTECH SAU (“GEMA”)
Under a manufacture and supply agreement, as amended, with GEMA related to the API for MOLBREEVI, the Company must make certain payments to GEMA upon achievement of the milestones outlined in the table set forth below. Additionally, upon first receipt of marketing approval by the Company from a regulatory authority in a country for a product containing the API supplied by GEMA for therapeutic use in humans and ending the earlier of (i) ten (10) years thereafter or (ii) the date a biosimilar of such product is first sold in such country, the Company shall pay GEMA a royalty equal to low-single digits of the net sales in that country.
Additionally, the Company is subject to a purchase requirement under which for ten years following the date of receipt of approval by a regulatory authority of the first regulatory filing for the marketing and sale of the first product containing the API supplied by GEMA in any country, the Company will purchase from GEMA the API required to produce a percentage of such product it sells each year (the “Purchase Requirement”); provided, however, that the Purchase Requirement will no longer apply if (i) the price charged by GEMA exceeds a certain price charged by an alternative supplier, (ii) there is a shortage of supply, or (iii) GEMA at any time fails to materially fulfill a purchase order of the Company.
13
PARI Pharma GmbH (“PARI”)
The Company is also subject to certain contingent milestone payments, disclosed in the table set forth below, payable to PARI, the manufacturer of the proprietary nebulizer used to administer MOLBREEVI. In addition to these milestones, the Company will owe PARI a royalty of three-and one-half percent (
3.5
%) based on net sales.
Milestone Payments
The following table summarizes manufacturing commitments and contingencies as of the period indicated (in thousands):
September 30, 2025
GEMA:
Achievement of certain milestones related to validation of API supplied by GEMA and
regulatory approval of MOLBREEVI drug substance produced at GEMA
$
230
PARI:
Achievement of various development activities and regulatory approval of proprietary
nebulizer utilized to administer MOLBREEVI
587
Total manufacturing and other commitments and contingencies
$
817
The milestone commitments disclosed in the table above reflect the activities that have (i) not been met or incurred; (ii) not been remunerated; and (iii) not accrued, as the activities are not deemed probable or reasonably estimable, as of September 30, 2025.
Contract Research
As part of its development of MOLBREEVI for the treatment of autoimmune PAP, the Company entered into a Master Services Agreement (“MSA”) with Parexel International (IRL) Limited (“Parexel”) pursuant to which Parexel will provide contract research services related to clinical trials. Contemporaneously with entering the MSA in January 2021, a work order was executed with Parexel, under which they provide services related to the IMPALA-2 trial. From inception of the original work order and subsequent change orders through trial close-out activities, the Company will have paid Parexel service fees, pass-through expenses, and investigator fees estimated to be approximately
$
49.3
million over the course of the IMPALA-2 clinical trial.
In the second quarter of 2024, the Company initiated an open-label, multicenter clinical trial of MOLBREEVI in pediatric subjects with autoimmune PAP ("IMPACT") under a separate work order with Parexel. Pursuant to the IMPACT trial, Parexel has the opportunity to earn up to approximately
$
5.6
million in various milestone payments primarily dependent upon patient enrollment, site management, project oversight and the compliance with defined study protocols.
Risk Management
The Company maintains various forms of insurance that the Company's management believes are adequate to reduce the exposure to certain risks associated with operating the Company’s business to an acceptable level.
Litigation
On September 8, 2025, a stockholder filed putative securities class action claims against the Company and certain of our executive officers in the United States District Court for the Eastern District of Pennsylvania, purportedly on behalf of classes of the Company’s investors who purchased or otherwise acquired the Company’s common stock and securities between March 7, 2024 and May 23, 2025. The complaint alleges violations of various sections of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder in connection with various public statements made by the Company regarding its regulatory and BLA filings for MOLBREEVI as a therapy to treat patients with autoimmune PAP. The actions seek unspecified damages, costs and expenses, including attorneys’ fees.
The Company intends to vigorously defend against such allegations. Given the nature of the cases, including that the proceedings are in their early stages, the Company is unable to predict the ultimate outcome of the cases or estimate the range of potential loss, if any.
From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.
14
10. Stock-Based Compensation
Equity Incentive Plans
The Company’s 2024 Omnibus Incentive Plan (the “2024 Plan”) was adopted by the Company’s board of directors in March 2024, was approved by the Company’s stockholders on June 6, 2024, and became effective on June 7, 2024. The 2024 Plan was intended to replace the Company’s Amended and Restated 2015 Omnibus Incentive Plan (the “2015 Plan”), and upon the effectiveness of the 2024 Plan, no further grants may be made under the 2015 Plan. All outstanding awards under the 2015 Plan will continue in accordance with the 2015 Plan and any award agreement executed in connection with such outstanding awards. The 2024 Plan provides for the grant of stock options (both incentive stock options and non-statutory stock options), stock appreciation rights, restricted stock, restricted stock units (“RSUs”), performance units, shares, and other stock-based awards. Stock-based awards are subject to terms and conditions established by the board of directors or the compensation committee of the board of directors. As of September 30, 2025, the number of shares of common stock available for grant under the 2024 Plan was
7,979,152
shares.
The Company’s 2021 Inducement Equity Incentive Plan (the “Inducement Plan”) was adopted by the Company’s board of directors in May 2021 and subsequently amended to increase the shares available for grant. The Inducement Plan provides for the grant of non-statutory stock options, restricted stock, RSUs, stock appreciation rights, performance units, and performance shares. Each award under the Inducement Plan is intended to qualify as an employment inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4). As of September 30, 2025, the number of shares of common stock available for grant under the Inducement Plan was
1,032,579
shares.
The Savara Inc. Stock Option Plan (the “2008 Plan”) was adopted in 2008, and the Company
no
longer issues awards under the 2008 Plan. As of
September 30, 2025, the Company had options outstanding to purchase
139,332
shares of common stock under the 2008 Plan. The outstanding awards granted under the 2008 Plan are fully vested and generally have a maximum contractual term of
ten years
.
Stock-Based Awards Activity
The following table provides a summary of stock-based awards activity for the
nine months ended September 30, 2025:
Stock Options:
Outstanding at December 31, 2024
13,554,621
Granted
309,500
Exercised
(
144,500
)
Expired/cancelled/forfeited
(
509,750
)
Outstanding at September 30, 2025
13,209,871
The total compensation cost related to non-vested stock options not yet recognized as of September 30, 2025, was
$
14.1
million, which will be recognized over a weighted-average period of approximately
2.9
years
.
RSUs:
Outstanding at December 31, 2024
4,677,500
Granted
335,500
Vested
(
400,000
)
Forfeited
(
520,000
)
Outstanding at September 30, 2025
4,093,000
The total compensation cost related to unvested RSUs not yet recognized as of September 30, 2025, was
$
5.3
million, which will be recognized over a weighted-average period of approximately
1.0
years
.
Stock-Based Compensation
Stock-based compensation expense is included in the following line items in the accompanying statements of operations and comprehensive loss for the
three and nine months ended September 30, 2025 and 2024 (in thousands):
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Research and development
$
1,107
$
1,076
$
2,398
$
2,980
General and administrative
2,318
1,295
6,668
3,844
Total stock-based compensation
$
3,425
$
2,371
$
9,066
$
6,824
15
11. Segment Reporting
We follow the accounting guidance of ASC Topic 280,
Segment Reporting, which establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers.
Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision-makers in deciding how to allocate resources and assess performance. The Company’s chief operating decision maker (“CODM”) has been identified as the
Chief Executive Officer
, who reviews consolidated results including operating expenses and operating losses at a consolidated level only. The Company and its CODM do not distinguish between potential markets for the purpose of making decisions about resource allocation and performance assessment of its sole pre-revenue development program, MOLBREEVI, for the treatment of
autoimmune PAP
. Therefore, the Company has only
one
operating segment and
one
reportable segment, specialty pharmaceuticals within the respiratory system. The Company's only significant long-lived asset, IPR&D, is located in Denmark, and
the Company currently does not generate any revenues and its operating expenses and losses are viewed on a consolidated basis by the CODM.
Therefore, no geographical segments are presented.
In addition to the significant expense categories included on the Company's consolidated statements of operations, refer below for disaggregated amounts that comprise research and development expenses and the segment net loss (in thousands):
For the three months ended September 30,
For the nine months ended September 30,
2025
2024
2025
2024
Operating expenses:
Research and development operating costs expenses
excluding non-cash stock-based compensation:
Primary program research and development expenses
(a)
$
15,414
$
15,726
$
46,862
$
41,769
Payroll and benefits
3,514
2,890
9,611
8,493
Occupancy and other overhead and operating costs
557
619
1,631
1,493
Total other research and development expenses
4,071
3,509
11,242
9,986
Research and development operating expenses
excluding non-cash stock-based compensation:
19,485
19,235
58,104
51,755
General and administrative expense excluding non-cash
stock-based compensation
7,309
4,718
22,860
13,345
Other segment income (expense), net
(b)
2,767
295
5,637
1,737
Segment net loss
$
(
29,561
)
$
(
24,248
)
$
(
86,601
)
$
(
66,837
)
a)
Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.
b)
Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation,
loss on extinguishment of debt (for the nine months ended September 30, 2025)
and tax credit income.
16
12. Net Loss per Share
Basic and diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and pre-funded warrants outstanding during the period without consideration of common stock equivalents. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Diluted net loss per share is the same as basic net loss per common share since the effects of potentially dilutive securities are antidilutive.
The following equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:
Nine months ended September 30,
2025
2024
Awards under equity incentive plan
13,209,871
9,478,496
Non-vested restricted shares and restricted stock units
4,093,000
3,753,562
Warrants to purchase common stock(*)
77,793
77,793
Total
17,380,664
13,309,851
* Pre-funded warrants are excluded herein.
The following table calculates basic earnings per share of common stock and diluted earnings per share of common stock for the
three and nine months ended September 30, 2025 and 2024 (in thousands, except share and per share amounts):
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Net loss
$
(
29,561
)
$
(
24,248
)
$
(
86,601
)
$
(
66,837
)
Net loss attributable to common
stockholders
(
29,561
)
(
24,248
)
(
86,601
)
(
66,837
)
Undistributed earnings and net loss
attributable to common stockholders,
basic and diluted
(
29,561
)
(
24,248
)
(
86,601
)
(
66,837
)
Weighted-average common shares
outstanding, basic and diluted
216,462,161
211,847,651
216,347,963
192,398,514
Basic and diluted net loss per share
$
(
0.14
)
$
(
0.11
)
$
(
0.40
)
$
(
0.35
)
13. Subseq
uent Events
The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and determined there were no events, other than as described below, that required disclosure or recognition in these condensed consolidated financial statements.
October 2025 Underwritten Public Offering of Common Stock
On October 31, 2025, the Company sold pursuant to an underwritten public offering (i) an aggregate of 28,452,381 shares of the Company’s common stock for $4.20 per share, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, and (ii) pre-funded warrants to purchase an aggregate of 7,142,857 shares of common stock at an exercise price of $0.001 per share (the “2025 Pre-Funded Warrants”) for $4.199 per pre-funded warrant (collectively, the “October 2025 Offering”). The October 2025 Offering was offered by the Company pursuant to the 2024 Registration Statement, and a prospectus supplement filed with the SEC on October 30, 2025.
The October 2025 Offering resulted in net proceeds to the Company of approximately $140.0 million, after deducting final underwriting discounts, commissions, and other estimated offering expenses. The Company intends to use the net proceeds for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of and pursuing regulatory approval for MOLBREEVI, investing in our commercialization infrastructure and supply, commercial launch preparation activities in the United States and European Union and general and administrative expenses.
17
Royalty Purchase and Sale Agreement
On October 29, 2025, we announced our entry into a purchase and sale agreement (the “Purchase Agreement”) with funds managed by RTW Investments, LP (the “Purchaser”). Under the terms of the Purchase Agreement, the Purchaser has agreed to pay us $
75.0
million (the “Purchase Price”) upon approval of MOLBREEVI by the FDA on or before March 31, 2027 and subject to satisfaction of other customary closing conditions, in exchange for a true sale of assigned interests, including the right to receive royalty payments equal to a percentage of Net Sales (as defined in the Purchase Agreement) of MOLBREEVI in the U.S. The royalty rate is tiered, with the payments ranging from
7.0
% to
1.0
% of Net Sales in each calendar year, with the
7.0
% tier increasing to
9.5
% for a calendar year if the prior year’s Net Sales do not achieve a specified level. The royalty payments commence in the first calendar quarter in which there is a commercial sale of MOLBREEVI in the United States and end upon the receipt by the Purchaser of $
187.5
million (the “Maximum Payment”). The Purchase Agreement includes a buy-back option that may allow us to pay a specified amount up to the Maximum Payment to terminate the Purchase Agreement and all obligations in the event of certain changes of control within two years of receipt of the Purchase Price. Unless otherwise agreed with the Purchaser, we are required to use a portion of the Purchase Price to repay all outstanding indebtedness. The Purchase Agreement contains customary affirmative and negative covenants, including covenants that limit or restrict the Company’s ability to, among other things, incur indebtedness (which restrictions are eliminated after the achievement by the Company of a specified amount of Net Sales), and other provisions customary for transactions of this nature, in each case subject to certain exceptions set forth in the Purchase Agreement.
18
Item 2. Ma
n
agement's Discussion and Analysis of Financial Condition and Results of Operations
This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements contained herein that involve risks and uncertainties, such as Savara’s plans, objectives, expectations, intentions, and beliefs should be considered forward-looking statements. Savara’s actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the risks associated with the process of conducting clinical trials and developing, obtaining regulatory approval for and commercializing drug candidates that are safe and effective for use as human therapeutics, the timing and ability to raise additional capital as needed to fund continued operations, natural disasters, pandemics, geopolitical events (including the war between Russia and Ukraine and the war in the Middle East), the Company’s ability to maintain compliance with its covenants under its long-term debt instruments and those risks and uncertainties discussed in the section entitled “Risk Factors” in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") on March 27, 2025, all of which are difficult to predict.
Statements made herein are as of the date of the filing of this Quarterly Report with the SEC and should not be relied upon as of any subsequent date. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
The following discussion and analysis of the financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and the consolidated financial statements and related notes in our Annual Report on Form 10-K for the year ended December 31, 2024.
Overview
Savara Inc. (together with its subsidiaries “Savara,” the “Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our sole program, MOLBREEVI, an inhaled biologic, is a granulocyte-macrophage colony-stimulating factor ("GM-CSF") in development for autoimmune pulmonary alveolar proteinosis ("autoimmune PAP"). Savara previously announced positive top-line results from IMPALA-2, the Phase 3 clinical trial of MOLBREEVI in autoimmune PAP and the submission of the Biologics License Application ("BLA") to the FDA for MOLBREEVI in autoimmune PAP. In May 2025, Savara announced the Company had received a Refusal to File ("RTF") letter from the FDA. The RTF was not the result of safety concerns, and the FDA did not request or recommend additional efficacy studies. The RTF does not impact previous designations granted by regulators for MOLBREEVI in autoimmune PAP. MOLBREEVI in autoimmune PAP has been granted Fast Track and Breakthrough Therapy Designations by the FDA, Orphan Drug Designation by the FDA and the European Medicines Agency (EMA), as well as Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). The Company plans to resubmit the BLA in December 2025 and request Priority Review. Savara, together with its wholly-owned subsidiaries, which include Aravas Inc. and Savara ApS, operate in one segment with its principal office in Langhorne, Pennsylvania, though a majority of our employees work remotely.
Since inception, we have devoted our efforts and resources to identifying and developing our product candidates, recruiting personnel, and raising capital. We have incurred operating losses and negative cash flow from operations and have no product revenue from inception to date. From inception to September 30, 2025, we have raised net cash proceeds of approximately $597.9 million, primarily from underwritten offerings of our common stock, private placements of common stock, and debt financings.
We have never been profitable and have incurred operating losses every year since inception. Our net losses for the three months ended September 30, 2025 and 2024 were $29.6 million and $24.2 million, respectively, and our net losses for the nine months ended September 30, 2025 and 2024 were $86.6 million and $66.8 million, respectively. The net loss for the year ended December 31, 2024 was $95.9 million. As of September 30, 2025, we had an accumulated deficit of approximately $575.9 million. Our operating losses primarily resulted from expenses attributed to our research and development programs and from general and administrative costs associated with our operations.
19
We have chosen to operate by outsourcing our manufacturing and most of our clinical operations. We expect to incur significant additional expenses and continue to incur operating losses for at least the next several years as we continue the clinical development of, and seek regulatory approval for, our primary product candidate. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to the timing of clinical development programs and efforts to achieve regulatory approval.
As of September 30, 2025, we had cash and cash equivalents of $16.3 million and short-term investments of $108.1 million. Additionally, on October 31, 2025 the Company completed a public offering of its common stock and certain pre-funded warrants which resulted in net proceeds to the Company of approximately $140.0 million, after deducting final underwriting discounts, commissions, and other estimated offering expenses and including the underwriter's option to purchase additional shares of our common stock at the public offering price. We will continue to require additional capital to continue our clinical development and potential commercialization activities. Although we have sufficient capital to fund many of our planned activities, we may need to continue to raise additional capital to further fund the development of, and seek regulatory approvals for, our product candidate and begin to commercialize any approved product. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidate.
Recent Events
October 2025 Underwritten Public Offering of Common Stock
On October 31, 2025, the Company sold pursuant to an underwritten public offering (i) an aggregate of 28,452,381 shares of the Company’s common stock for $4.20 per share, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, and (ii) pre-funded warrants to purchase an aggregate of 7,142,857 shares of common stock at an exercise price of $0.001 per share (the “2025 Pre-Funded Warrants”) for $4.199 per pre-funded warrant (collectively, the “October 2025 Offering”). The October 2025 Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-279274), which was previously filed with the Securities Exchange Commission on May 9, 2024 and declared effective on May 21, 2024, and a prospectus supplement filed with the SEC on October 30, 2025.
The October 2025 Offering resulted in net proceeds to the Company of approximately $140.0 million, after deducting final underwriting discounts, commissions, and other estimated offering expenses. The Company intends to use the net proceeds for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of and pursuing regulatory approval for MOLBREEVI, investing in our commercialization infrastructure and supply, commercial launch preparation activities in the United States and European Union and general and administrative expenses.
Royalty Purchase and Sale Agreement
On October 29, 2025, we announced our entry into a purchase and sale agreement (the “Purchase Agreement”) with funds managed by RTW Investments, LP (the “Purchaser”). Under the terms of the Purchase Agreement, the Purchaser has agreed to pay us $75.0 million (the “Purchase Price”) upon approval of MOLBREEVI by the FDA on or before March 31, 2027 and subject to satisfaction of other customary closing conditions, in exchange for a true sale of assigned interests, including the right to receive royalty payments equal to a percentage of Net Sales (as defined in the Purchase Agreement) of MOLBREEVI in the U.S. The royalty rate is tiered, with the payments ranging from 7.0% to 1.0% of Net Sales in each calendar year, with the 7.0% tier increasing to 9.5% for a calendar year if the prior year’s Net Sales do not achieve a specified level. The royalty payments commence in the first calendar quarter in which there is a commercial sale of MOLBREEVI in the United States and end upon the receipt by the Purchaser of $187.5 million (the “Maximum Payment”). The Purchase Agreement includes a buy-back option that may allow us to pay a specified amount up to the Maximum Payment to terminate the Purchase Agreement and all obligations in the event of certain changes of control within two years of receipt of the Purchase Price. Unless otherwise agreed with the Purchaser, we are required to use a portion of the Purchase Price to repay all outstanding indebtedness. The Purchase Agreement contains customary affirmative and negative covenants, including covenants that limit or restrict the Company’s ability to, among other things, incur indebtedness (which restrictions are eliminated after the achievement by the Company of a specified amount of Net Sales), and other provisions customary for transactions of this nature, in each case subject to certain exceptions set forth in the Purchase Agreement.
Government Shutdown
Effective October 1, 2025, the U.S. federal government shutdown due to the inability of the U.S. Congress to appropriate new funding for its 2026 budget, significantly impacting the FDA. While the FDA continues certain critical functions funded by user fees and public health exemptions, many non-essential activities have ceased or are experiencing delays. During
20
this shutdown, the FDA is not accepting new drug applications, abbreviated new drug applications for generics, or BLA's. The review of pending drug applications that were submitted with user fees paid prior to the shutdown is expected to continue to the extent such proceeds are sufficient for the FDA to perform its regulatory operations; however, we cannot assure investors that the shutdown, if not lifted in the near term, will not impact the timing for acceptance or review of our BLA following our submission.
Financial Operations Overview
Research and Development Expenses
We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following:
•
expenses incurred under agreements with contract research organizations (“CROs”), consultants, and clinical trial sites that conduct research and development activities on our behalf;
•
laboratory and vendor expenses related to the execution of our clinical trials;
•
contract manufacturing expenses, primarily for the production of clinical supplies; and
•
internal costs that are associated with activities performed by our research and development organization, consisting primarily of:
o
personnel costs, which include salaries, benefits, and stock-based compensation expense;
o
facilities and other expenses, which include expenses for maintenance of facilities and depreciation expense; and
o
regulatory expenses and technology license fees related to development activities.
We expect research and development expenses will remain significant in the future as we advance our MOLBREEVI product candidate through clinical trials and pursue regulatory approvals, which will require a significant increased investment in regulatory support and contract manufacturing activities, including investing in the development of a second source manufacturer and clinical supplies.
The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely developing and achieving regulatory approval for our product candidate. The probability of success of our product candidate may be affected by numerous factors, including clinical data, competition, intellectual property rights, manufacturing capability, and commercial viability. As a result, we are unable to accurately determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of MOLBREEVI.
General and Administrative Expenses
General and administrative
("G&A") expenses consist primarily of salaries, benefits, and related costs for personnel in executive, finance and accounting, legal, and investor relations; as well as professional and consulting fees for accounting, legal, investor relations, business development, human resources, and information technology services. Other G&A expenses include facility lease and insurance costs.
Other Income (Expense), Net
Other income (expense) includes amortization expense related to capitalized debt issuance costs and debt discount under our loan agreements. Refer to
Note 6. Debt Facility
in the notes to the condensed consolidated financial statements included in this Quarterly Report. Interest expense is typically reported net of interest income which includes interest earned on our cash, cash equivalent, and short-term investment balances. Other income (expense) also includes net unrealized and realized gains and losses from foreign currency transactions, loss on extinguishment of debt, refundable tax credits generated by some of our foreign subsidiaries, and securities subject to fair value accounting as well as any other non-operating gains and losses.
Critical Accounting Policies and Estimates
There have not been any material changes during the nine months ended September 30, 2025, to the methodology applied by management for critical accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024. Please read
Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates
in our Annual Report on Form 10-K for the year ended December 31, 2024, for further description of our critical accounting policies.
21
Results of Operations – Comparison of Three Months Ended September 30, 2025 and 2024
For the Three Months Ended September 30,
Dollar
2025
2024
Change
(in thousands)
Operating expenses:
Research and development
$
20,592
$
20,311
$
281
General and administrative
9,627
6,013
3,614
Depreciation and amortization
36
33
3
Total operating expenses
30,255
26,357
3,898
Loss from operations
(30,255
)
(26,357
)
(3,898
)
Other income, net
694
2,109
(1,415
)
Net loss
$
(29,561
)
$
(24,248
)
$
(5,313
)
Research and Development
Research and development expenses increased by $0.3 million, or 1.4%, to $20.6 million for the three months ended September 30, 2025 from $20.3 million for the three months ended September 30, 2024. This increase is primarily due to the performance of tasks related to our MOLBREEVI program, which includes approximately $0.3 million of costs related to our chemistry, manufacturing, and controls activities, primarily driven by initiatives to establish our additional drug substance manufacturer, $0.9 million of costs related to regulatory affairs and quality assurance and $0.6 million other departmental overhead, partially offset by a decrease of $1.5 million of clinical costs.
General and Administrative
General and administrative expenses increased by $3.6 million, or 60.1%, to $9.6 million for the three months ended September 30, 2025 from $6.0 million for the three months ended September 30, 2024. The increase is primarily attributable to the strategic addition of personnel and related costs of $2.9 million, certain commercial activities of $0.2 million, and other departmental overhead of $0.5 million.
Other Income, Net
Other income, net decreased by $1.4 million to $0.7 million for the three months ended September 30, 2025 from $2.1 million for three months ended September 30, 2024. The decrease is primarily due to lower interest rates and lower investment balances.
Results of Operations – Comparison of Nine Months Ended September 30, 2025 and 2024
Nine months ended September 30,
Dollar
2025
2024
Change
(in thousands)
Operating expenses:
Research and development
$
60,502
$
54,735
$
5,767
General and administrative
29,528
17,189
12,339
Depreciation and amortization
98
98
—
Total operating expenses
90,128
72,022
18,106
Loss from operations
(90,128
)
(72,022
)
(18,106
)
Other income, net
3,527
5,185
(1,658
)
Net loss
$
(86,601
)
$
(66,837
)
$
(19,764
)
Research and Development
Research and development expenses increased by $5.8 million, or 10.5%, to $60.5 million for the nine months ended September 30, 2025 from $54.7 million for the nine months ended September 30, 2024. This increase is primarily due to the performance of tasks related to our MOLBREEVI program, which includes approximately $4.1 million of costs related to our chemistry, manufacturing, and controls activities, primarily driven by initiatives to establish our additional drug substance manufacturer, $4.3 million of costs related to regulatory affairs and quality assurance and $0.7 million other departmental overhead, partially offset by a decrease of $3.3 million of clinical costs.
22
General and Administrative
General and administrative expenses increased by $12.3 million, or 71.8%, to $29.5 million for the nine months ended September 30, 2025 from $17.2 million for the nine months ended September 30, 2024. The increase is primarily attributable to the strategic addition of personnel and related costs of $7.8 million, certain commercial activities of $2.5 million, and other departmental overhead of $2.0 million.
Other Income, Net
Other income, net decreased by $1.7 million to $3.5 million for the nine months ended September 30, 2025 from $5.2 million for the nine months ended September 30, 2024. The decrease is primarily related to lower interest rates and loss on extinguishment of debt, partially offset by a gain on foreign currency translation rates.
Liquidity and Capital Resources
As of September 30, 2025, we had $16.3 million of cash and cash equivalents, $108.1 million in short-term investments, and an accumulated deficit of approximately $575.9 million. As discussed in
Note 6. Debt Facility
in the notes to the condensed consolidated financial statements included in this Quarterly Report, on March 26, 2025, we entered into the Hercules Loan Agreement which provides for a loan facility of up to $200 million. Proceeds from the initial $30 million tranche drawn under the Hercules Loan Agreement, with a carrying value of $29.8 million, were used to repay all outstanding obligations under the SVB Loan, pay certain expenses incurred in connection with the financing, and for general corporate purposes. Subject to satisfaction of certain conditions, including attainment of FDA approval of MOLBREEVI for the treatment of autoimmune PAP, we may draw future tranches under the Hercules Loan Agreement to fund our ongoing business operations including the development, regulatory approval, marketing and commercialization of MOLBREEVI. Refer to
Note 6. Debt Facility
of the unaudited condensed consolidated financial statements in this quarterly report on Form 10-Q for additional discussion.
On March 31, 2025, pursuant to Section 12(b) of the ATM Agreement, the Company delivered written notice to Evercore that it was terminating the ATM Agreement, effective April 2, 2025.
In addition, we completed the October 2025 Offering resulted in net proceeds to the Company of approximately $140.0 million, after deducting final underwriting discounts, commissions, and other estimated offering expenses and including the underwriter's option to purchase additional shares of our common stock at the public offering price.
We have used and intend to use our liquidity and capital for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of and pursuing regulatory approval for MOLBREEVI, investing in our commercialization infrastructure and supply, commercial launch preparation activities in the United States and European Union and general and administrative expenses.
Cash Flows
The following table summarizes our cash flows for the periods indicated:
Nine months ended September 30,
2025
2024
(in thousands)
Cash used in operating activities
$
(75,980
)
$
(65,807
)
Cash provided by (used in) investing activities
75,124
(57,836
)
Cash provided by financing activities
2,246
118,420
Effect of exchange rate changes on cash and cash equivalents
(241
)
65
Net change in cash and cash equivalents
$
1,149
$
(5,158
)
Cash flows from operating activities
Cash used in operating activities for the nine months ended September 30, 2025 was $76.0 million, consisting of a net loss of $86.6 million offset by $2.8 million in changes to operating assets and liabilities and $7.8 million of net noncash charges. Net noncash charges are comprised of depreciation and amortization including right-of-use assets, amortization of debt issuance costs, loss on extinguishment of debt, accretion on discount to short-term investments, and stock-based compensation.
Cash flows from investing activities
Cash used in investing activities of $75.1 million for the nine months ended September 30, 2025 was primarily associated with proceeds from maturities of short-term investments partially offset by purchases of short-term investments.
23
Cash flows from financing activities
Cash provided by financing activities of $2.2 million for the nine months ended September 30, 2025 was primarily the result of net proceeds from the Hercules Loan Agreement partially offset by repayment of the SVB Loan.
Future Funding Requirements
We have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize our product candidate. At the same time, we expect our expenses to increase in connection with our ongoing development and manufacturing activities, particularly as we continue the research, development, manufacture, and clinical trials of, and seeking regulatory approval for, our product candidate. In addition, subject to obtaining regulatory approval of our product candidate, we anticipate we may need additional funding in connection with our continuing operations.
As of September 30, 2025, we had cash, cash equivalents, and short-term investments of approximately $124.4 million. Although we have sufficient capital to fund our planned activities, including those discussed in
Note 9. Commitments – Manufacturing and Other Commitments and Contingencies
, in the notes to the condensed consolidated financial statements included in this Quarterly Report, we may need to raise additional capital to further fund the development of, and seek regulatory approvals for, our product candidate and to begin commercialization of any approved product. For instance, we completed the October 2025 Offering which resulted in net proceeds to the Company of approximately $140.0 million, after deducting final underwriting discounts, commissions, and other estimated offering expenses and including the underwriter's option to purchase additional shares of our common stock at the public offering price.
The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidate.
Although we believe we are well capitalized based on our current operations, until we can generate a sufficient amount of product revenue to finance our cash requirements, we may finance our future cash needs primarily through the issuance of additional equity securities and potentially through borrowings, grants, and strategic alliances with partner companies. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or commercialization efforts or grant rights to develop and market our product candidate to third parties that we would otherwise prefer to develop and market ourselves.
Critical Accounting Policies and Estimates
Except as set forth in
Note 2. Summary of Significant Accounting Policies – Recent Accounting Pronouncements
of the condensed consolidated financial statements in this Quarterly Report, there have been no material changes in our critical accounting policies and use of estimates during the nine months ended September 30, 2025 as compared to those disclosed in “
Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates
” in the our Annual Report on Form 10-K for the year ended December 31, 2024.
24
Item 3. Quantitative and Qualitati
ve Disclosures About Market Risk.
Market Risk
We have market risk exposure related to our cash, cash equivalents, and short-term investment securities. Such interest-earning instruments carry a degree of interest rate risk; however, we have not been exposed, nor do we anticipate being exposed, to material risks due to changes in interest rates. A hypothetical 1% change in interest rates during any of the periods presented would not have a material impact on our condensed consolidated financial statements. Additionally, our investment securities are fixed income instruments denominated and payable in U.S. dollars and have short-term maturities, typically less than twelve months, and typically carry credit ratings of “A” at a minimum by two of three Nationally Recognized Statistical Rating Organizations, specifically Moody’s, Standard & Poor’s, or Fitch. As such, we do not believe that our cash, cash equivalents, and short-term investment securities have significant risk of default or illiquidity.
Interest Rate Risk
We also have interest rate exposure related to our long-term debt. Refer to
Note 6. Debt Facility
of the unaudited condensed consolidated financial statements in this quarterly report on Form 10-Q for additional discussion. The Hercules Loan Agreement bears interest equal to the greater of (i) the prime rate reported in The Wall Street Journal, plus 1.45%, which was 8.7% on September 30, 2025. Changes in the prime rate would have impacted our interest expense associated with our secured term loan. If a 10% change in interest rates from the interest rates on September 30, 2025, were to have occurred, this change would not have had a material effect on our interest expense with respect to outstanding borrowed amounts.
Foreign Currency Exchange Risk
We use the U.S. Dollar ("USD") as our functional and reporting currency, and therefore, are subject to the risk of fluctuations in foreign currency exchange rates. The financial statements of the Company’s wholly-owned subsidiaries are recorded in their functional currency and translated into USD. Our foreign currency exchange rate risk is primarily related to translation of our assets and liabilities from our foreign subsidiaries' functional currencies to USD. The cumulative effect of changes in exchange rates between the foreign entity’s functional currency and the reporting currency is reported in
Accumulated other comprehensive gain (loss)
in the condensed consolidated balance sheet.
Additionally, we have vendors in Denmark, elsewhere in Europe, and the United Kingdom and pay those vendors in local currency, Danish Krone, British Pound Sterling or Euros, respectively. Accordingly, our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro, British Pound Sterling and Danish Krone. Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the United States as well as the European Union and the United Kingdom. Our results of operations and cash flows may be adversely affected due to an expansion of non-U.S. dollar denominated contracts, growth of our international entities and operations and changes in foreign exchange rates or a weakening or strengthening of the USD against the Euro, British Pound Sterling and Danish Krone.
For nine months ended September 30, 2025 and 2024, we recognized a gain on foreign currency transactions of $0.7 million and $0.3 million, respectively, recorded as a component of other comprehensive income (loss) in our condensed statements of operations. In general, the effect of a hypothetical 10% change in foreign currency exchange rates applicable to our business on September 30, 2025 would not have a material impact on our on our results of operations or financial condition. We are currently not engaged in any hedging strategies. As our international operations grow, we will continue to reassess our approach to manage the risk relating to fluctuations in currency rates.
Inflation Risk
Additionally, inflation generally affects us by increasing our cost of labor, supplies and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented.
25
Ite
m 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management has evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial and Administrative Officer, the effectiveness of our disclosure controls and procedures as of September 30, 2025, pursuant to and as required by Rule 13a-15(b) under the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial and Administrative Officer have concluded that, as of September 30, 2025, our disclosure controls and procedures, as defined by Rule 13a-15(e) under the Exchange Act, were effective and designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (i) is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and (ii) information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial and Administrative Officer, as appropriate to allow timely decisions regarding required disclosures.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the nine months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
26
PA
RT II – OTHER INFORMATION
Ite
m 1. Legal Proceedings.
On September 8, 2025, a stockholder filed putative securities class action claims against the Company and certain of our executive officers in the United States District Court for the Eastern District of Pennsylvania, purportedly on behalf of classes of the Company’s investors who purchased or otherwise acquired the Company’s common stock and securities between March 7, 2024 and May 23, 2025. The complaint alleges violations of various sections of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder in connection with various public statements made by the Company regarding its regulatory and BLA filings for MOLBREEVI as a therapy to treat patients with autoimmune PAP. The actions seek unspecified damages, costs and expenses, including attorneys’ fees. We intend to vigorously defend against such allegations. Given the nature of the case, including that the proceedings are in their early stages, the Company is unable to predict the ultimate outcome of the cases or estimate the range of potential loss, if any.
From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.
Ite
m 1A. Risk Factors.
In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading “Item 1A. Risk Factors” included in the Annual Report on Form 10-K for the year ended December 31, 2024, and the risk factors and other cautionary statements contained in our other filings with the SEC, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, or future results. Except as noted below, there have been no material changes in our risk factors from those described in the Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 or our other SEC filings.
We are and may continue to be targets of securities-related class action and derivative lawsuits and defending against these claims could result in substantial costs and divert management time and resources and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, may be costly to defend or pursue and are uncertain in their outcome.
On September 8, 2025, a stockholder filed putative securities class action claims against the Company and certain of our executive officers in the United States District Court for the Eastern District of Pennsylvania, purportedly on behalf of classes of the Company’s investors who purchased or otherwise acquired the Company’s common stock and securities between March 7, 2024 and May 23, 2025. The complaint alleges violations of various sections of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder in connection with various public statements made by the Company regarding its regulatory and BLA filings for MOLBREEVI as a therapy to treat patients with autoimmune PAP.
The outcome of litigation is necessarily uncertain, and we cannot predict the outcome of these pending legal proceedings. An unfavorable outcome in any such proceeding could have an adverse impact on our business, financial condition, results of operations and cash resources. In addition, we may be exposed to additional litigation even if no wrongdoing occurred and we ultimately prevail. Continuing or additional litigation, or responding to any related investigation or enforcement action, as well as a material final judgment or decree against us, would be expensive, divert management’s attention and resources, and could adversely affect our business, financial condition, results of operations and cash resources. Moreover, if our stock price is volatile, we could face additional securities class action lawsuits in the future.
Ite
m 2. Unregistered Sales of Equity Securities, and Use of Proceeds.
None.
Ite
m 3. Defaults Upon Senior Securities.
None.
Ite
m 4. Mine Safety Disclosures.
Not applicable.
27
Ite
m 5. Other Information.
Rule 10b5-1 Trading Plans
During the quarter ended September 30, 2025
, no officer or director of the Company
adopted
or
terminated
any contract, instruction, or written plan for the purchase or sale of securities of the Company’s common stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement as defined in 17 CFR § 229.408(c).
Ite
m 6. Exhibits.
An Exhibit Index has been attached as part of this report and is incorporated by reference.
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Filed herewith
** Furnished herewith. The certification attached as Exhibits 32.1 that accompanies this quarterly report on Form 10-Q (Report) is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
29
SIGNA
TURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Savara Inc.
Date: November 12, 2025
By:
/s/ Matthew Pauls
Matthew Pauls
Chief Executive Officer and Chair of the Board of Directors
(We are using algorithms to extract and display detailed data. This is a hard problem and we are working continuously to classify data in an accurate and useful manner.)
